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Correction to:  J Transl Med (2018) 16:142  
https ://doi.org/10.1186/s1296 7-018-1507-6
Following publication of the original article [1], the 
authors reported an error in the spelling of one of the 
author names. In this Correction the incorrect and cor-
rect author names are indicated and the author name 
has been updated in the original publication. The 
authors also reported an error in the Methods section 
of the original article. In this Correction the incorrect 
and correct versions of the affected sentence are indi-
cated. The original article has not been updated with 
regards to the error in the Methods section.
Incorrect author name upon publication:
  • Tobias Walpert
The correct author name:
  • Tobias Walbert
The affected sentence in the Methods section upon 
publication, with the error marked in bold:
  • In general, approximately 2  g of tumor tissue 
was needed to produce the full ten doses for the 
36-month treatment and follow-up schedule. The 
vaccine was aliquoted in individual doses and cryo-
preserved at < 150 °C [22].
The corrected sentence, with the corrected tempera-
ture marked in bold:
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  • In general, approximately 2  g of tumor tissue 
was needed to produce the full ten doses for the 
36-month treatment and follow-up schedule. The 
vaccine was aliquoted in individual doses and cryo-
preserved at < − 150 °C [22].
The reference which is cited in the above sentence 
can be reviewed in the original article.
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